Different effects of simvastatin on ex vivo monocyte cytokine release in patients with hypercholesterolemia and impaired glucose tolerance.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Physiology and Pharmacology

• Publication date

  2010-12-01

• Fields of study

  Medicine

• Identifiers
  PMID 21224504
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of HMG-CoA Reductase Inhibitors on Coagulation and Fibrinolysis Processes

  2012cited by this paper
• The effect of fenofibrate on lymphocyte cytokine release in patients with impaired fasting glucose and impaired glucose tolerance: a preliminary report.

  2010cited by this paper
• Pleiotropic Effects of Atorvastatin and Fenofibrate in Metabolic Syndrome and Different Types of Pre-Diabetes

  2010cited by this paper
• Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances

  2010cited by this paper
• Inflammatory mechanisms in atherosclerosis

  2009cited by this paper
• Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy.

  2009cited by this paper
• Monocytes and vascular endothelial cells apoptosis. Role of p-HSP27.

  2009cited by this paper
• Macrophages: promising targets for the treatment of atherosclerosis.

  2009cited by this paper
• Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH).

  2009cited by this paper
• Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications.

  2009cited by this paper
• Increased pro-inflammatory activity and impairment of human monocyte differentiation induced by in vitro exposure to cigarette smoke.

  2009cited by this paper
• Pleiotropic Action of Short-Term Metformin and Fenofibrate Treatment, Combined With Lifestyle Intervention, in Type 2 Diabetic Patients With Mixed Dyslipidemia

  2009cited by this paper
• Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein (CRP)

  2009cited by this paper
• The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis.

  2009cited by this paper
• The metabolic syndrome - an ongoing story.

  2009cited by this paper
• Pleiotropic effects of statins--clinical evidence.

  2009cited by this paper
• Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus.

  2008cited by this paper
• Spectrum of pleiotropic effects of statins in heart failure.

  2008cited by this paper
• Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

  2008cited by this paper
• Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity.

  2007cited by this paper
• Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association

  2007cited by this paper
• Statins: a new insight into their mechanisms of action and consequent pleiotropic effects.

  2007cited by this paper
• Effects of Simvastatin and Metformin on Inflammation and Insulin Resistance in Individuals with Mild Metabolic Syndrome

  2007cited by this paper
• Inflammatory biomarkers in stable atherosclerosis.

  2006cited by this paper
• Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance.

  2006cited by this paper
• Cytokines in atherosclerosis: pathogenic and regulatory pathways.

  2006cited by this paper
• Monocyte suppressing action of fenofibrate.

  2005cited by this paper
• Effect of Monthly Atorvastatin and Fenofibrate Treatment on Monocyte Chemoattractant Protein-1 Release in Patients with Primary Mixed Dyslipidemia

  2005cited by this paper
• Monocyte Release of Tumor Necrosis Factor-α and Interleukin-1β in Primary Type IIa and IIb Dyslipidemic Patients Treated With Statins or Fibrates

  2005cited by this paper
• Impaired glucose tolerance and impaired fasting glucose — a review of diagnosis, clinical implications and management

  2005cited by this paper
• The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia.

  2004cited by this paper
• Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

  2004cited by this paper
• Pathobiology of atherosclerosis--a brief review.

  2004cited by this paper
• MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

  2003cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study

  2001cited by this paper

• Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?

  2024cites this paper
• The Immunomodulatory Effects of a 6-Month Extra Virgin Olive Oil Intervention on Monocyte Cytokine Secretion and Plasma Cytokine Levels in Dyslipidemic and Post-Infarct Patients: A Clinical Pilot Study

  2023cites this paper
• Nature versus Number: Monocytes in Cardiovascular Disease

  2021cites this paper
• Simvastatin therapy attenuates memory deficits that associate with brain monocyte infiltration in chronic hypercholesterolemia

  2021cites this paper
• Simvastatin Therapy Attenuates Memory Deficits that Associate to Brain Monocyte Infiltration in Chronic Hypercholesterolemic ApoE-/- Mice

  2020cites this paper
• Risk and Benefits of Statins in Glucose Control Management of Type II Diabetes

  2016cites this paper
• Hypercholesterolemia Induces Vascular Cell Dysfunction: Molecular Basis for Atherosclerosis

  2016cites this paper
• Effects of simvastatin on the osteogenic differentiation and immunomodulation of bone marrow mesenchymal stem cells.

  2015cites this paper
• Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory cytokine release in men and women with type 2 diabetes and atherogenic dyslipidemia.

  2015cites this paper
• Vitamin D Status and Its Relation with Abdominal Adiposity and Cardiovascular Risk Factors of Korean Adults in Certain Areas (Korean J Obes 2015;24:30-5)

  2015cites this paper
• Several statins increase body and liver fat accumulation in a model of metabolic syndrome.

  2013cites this paper
• Preparation and in vitro percutaneous penetration of simvastatin ethosome gel

  2013cites this paper
• Altered monocyte calcium-sensing receptor expression in patients with type 2 diabetes mellitus and atherosclerosis.

  2013cites this paper
• Monocyte-suppressing effects of simvastatin in patients with isolated hypertriglyceridemia.

  2013cites this paper
• Atorvastatin does not impair endothelial cell wound healing in an in vitro model of vascular injury.

  2012cites this paper
• Preparation and In Vitro Evaluation of Simvastatin Ethosome

  2011cites this paper
• The common adiponutrin variant p.I148M does not confer gallstone risk but affects fasting glucose and triglyceride levels.

  2011cites this paper